Conference Schedules, Upcoming Marathon Applications, Revised Guidance, and Acquisitions - Analyst Notes on Celgene, Medtronic,

 Conference Schedules, Upcoming Marathon Applications, Revised Guidance, and
      Acquisitions - Analyst Notes on Celgene, Medtronic, Alexion, Quest
                          Diagnostics, and Illumina

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, March 14, 2014

NEW YORK, March 14, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Celgene
Corporation (NASDAQ: CELG), Medtronic, Inc. (NYSE: MDT), Alexion
Pharmaceuticals, Inc. (NASDAQ: ALXN), Quest Diagnostics Inc (NYSE: DGX) and
Illumina, Inc. (NASDAQ: ILMN). Private wealth members receive these notes
ahead of publication. To reserve complementary membership, limited openings
are available at:


Celgene Corporation Analyst Notes

On its events page, Celgene Corporation (Celgene) posted the schedule of two
upcoming conferences that the Company will participate in during the ongoing
month. Celgene will be a part of the American Academy of Dermatology (AAD)
Annual Meeting at the Colorado Convention Center in Denver, CO, which will be
held from March 21 to March 25, 2014. The Company will also take part in the
European Lung Cancer Conference (ELCC) at Palexpo in Geneva, Switzerland,
which will take place from March 26 to March 29, 2014. The full analyst notes
on Celgene Corporation are available to download free of charge at:


Medtronic, Inc. Analyst Notes

On March 10, 2014, Medtronic, Inc. (Medtronic) announced that the applications
for runners around the world who benefit from medical technology to represent
their country on the 2014 Medtronic Global Heroes team are now open. According
to Medtronic, up to 25 runners will be chosen to receive a paid entry for
themselves and a guest to the Medtronic Twin Cities Marathon or the Medtronic
TC 10 Mile. The Company informed that the 2014 Medtronic Twin Cities Marathon
weekend will take place from October 3 to October 5, 2014, and that the
deadline for application is April 25, 2014. The full analyst notes on
Medtronic, Inc. are available to download free of charge at:


Alexion Pharmaceuticals, Inc. Analyst Notes

On March 10, 2014, Alexion Pharmaceuticals, Inc. (Alexion) revised its
previously announced 2014 financial guidance for net product sales and
non-GAAP earnings per share (EPS). Alexion stated that its 2014 net revenue
guidance has been increased to a range of $2,150 to $2,170 million from its
prior guidance range of $2,000 to $2,020 million. The Company said that it
will record increased revenue in 2014 related to an agreement that brings to
conclusion discussions with the French government and which positively impacts
prospective reimbursement of Soliris. Non-GAAP EPS is now expected in the
range of $4.37 to $4.47, up from the Company's previous expectation of $3.70
to $3.80. The full analyst notes on Alexion Pharmaceuticals, Inc. are
available to download free of charge at:


Quest Diagnostics Inc. Analyst Notes

On March 11, 2014, Quest Diagnostics Inc. (Quest Diagnostics) announced that
it has entered into an agreement to acquire Summit Health - a leading provider
of on-site prevention and wellness programs mainly for employees. Steve
Rusckowski, President and CEO, Quest Diagnostics, stated "This acquisition
supports Quest Diagnostics' five-point strategy, which includes restoring
growth and driving disciplined capital deployment. One of our capital
deployment objectives is to grow one to two percent a year through
strategically aligned, accretive acquisitions." Terms of the transaction were
not disclosed. The full analyst notes on Quest Diagnostics Inc. are available
to download free of charge at:


Illumina, Inc. Analyst Notes

On March 10, 2014, Illumina, Inc. (Illumina) and WuXi PharmaTech (Cayman) Inc.
announced that the Wuxi Genome Center has purchased an Illumina HiSeq X Ten
sequencing system. The Company informed that HiSeq X Ten is the world's first
platform to deliver full coverage human genomes. Illumina stated that the
purchase will enable WuXi's clinical genomic services to expand from the
current target panel, exome, and transcriptome scale sequencing to population
genome scale sequencing, putting the world's most advanced gene sequencing
capability in the hands of the leading pharmaceutical R&D services company in
the Asia Pacific region. "This investment in cutting-edge gene sequencing
technology significantly strengthens WuXi's broad, integrated platform of R&D
services," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "It advances
our mission of enabling anyone and any company to use our R&D platform to
discover and develop innovative medicines to benefit the world's patients."
The full analyst notes on Illumina, Inc. are available to download free of
charge at:


About Analysts Review
We provide our members with a simple and reliable way to leverage our economy
of scale. Most investors do not have time to track all publicly traded
companies, much less perform an in-depth review and analysis of the
complexities contained in each situation. That's where Analysts Review comes
in. We provide a single unified platform for investors' to hear about what
matters. Situation alerts, moving events, and upcoming opportunities.




  oThis is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
  oInformation in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
  oThis information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
  oIf you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at pubco [at]
  oFor any urgent concerns or inquiries, please contact us at compliance [at]
  oAre you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to research [at] for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Analysts Review. An
outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Analysts Review in this article or
report according to the Procedures outlined by Analysts Review. Analysts
Review is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.


Analysts Review makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to be construed
as personal financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold any
securities mentioned herein.


Analysts Review is not responsible for any error which may be occasioned at
the time of printing of this document or any error, mistake or shortcoming. No
liability is accepted by Analysts Review whatsoever for any direct, indirect
or consequential loss arising from the use of this document. Analysts Review
expressly disclaims any fiduciary responsibility or liability for any
consequences, financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1) guarantee the
accuracy, timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The included
information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA

SOURCE Analysts Review

Contact: Adam Redford, +852-8191-3972
Press spacebar to pause and continue. Press esc to stop.